In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...
Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...
The stock's fall snapped a seven-day winning streak.
The company generated free cash flow of $722 million in Q4 and $2.7 billion for the year. Biogen issued downside guidance for 2025 with an EPS forecast between $15.25 to $16.25 versus $16.33.
Stoke will receive $165m upfront from Biogen upon completion of the transaction. The company is eligible for up to $385m in development and commercial milestone payments, plus tiered royalties on ...
The Green Party's new logo is an emoji. The federal party unveiled its new brand, a green dot, on Tuesday on Parliament Hill, possibly weeks before a snap federal election. "The great thing about ...
Meghan Markle's refreshed lifestyle brand has a logo with a meaningful symbol ... referencing the first product from the company that she sent to friends last year. "But there are so many more ...
CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ:STOK) have ...
CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ ...
CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...
Biogen on Tuesday agreed to pay $165 million upfront for exclusive rights to sell the drug, called zorevunersen, outside the U.S., Canada and Mexico. The company also agreed to split external ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results